Table 2.
Details of Included Studies (N=126)
| Study Details | n (%) |
|---|---|
| Region of origin of study participants | |
| Europe | 62 (49.20) |
| America (all) | 31 (24.60) |
| Asia | 17 (13.49) |
| America (Black Americans)* | 12 (9.53) |
| Africa | 4 (3.18) |
| Year thestudy started | |
| 1973–1998 | 54 (42.86) |
| 1999–2019 | 72 (57.14) |
| Study design | |
| Parallel | 108 (85.71) |
| Crossover | 18 (14.29) |
| Study duration, wk | |
| <12 | 55 (43.65) |
| 12–24 | 54 (42.86) |
| >24 | 17 (13.49) |
| Usage of antihypertensive medications | |
| Yes | 43 (34.13) |
| No | 65 (51.58) |
| Not reported | 18 (14.29) |
| Health status of recruited participants | |
| Hypertension and prehypertension (mixed) | 27 (21.43) |
| Hypertension only | 91 (72.22) |
| Prehypertension only | 8 (6.35) |
*
America (Black Americans) studies are those from America that were done in Black participants.